Utilization of bioelectrical impedance analysis for detection of lymphedema in breast Cancer survivors: a prospective cross sectional study

Sung Mook Lim†, Yujin Han†, Seung Il Kim1 and Hyung Seok Park1*

Abstract
Background: Breast cancer survivors are at risk of developing breast cancer-related lymphedema (BCRL) after surgical treatment, which may have a negative effect on quality of life. The purpose of this study was to investigate the clinical role of bioelectrical impedance analysis (BIA) and the relationship between the development of BCRL in breast cancer survivors who have undergone axillary surgery.

Methods: A total of 228 patients with breast cancer were enrolled in the study between May 2016 and January 2017. BCRL was assessed by measuring the circumference of both arms at 15 cm below the acromion process and the olecranon process. Patients were classified as BCRL (n = 22) and non-BCRL (n = 206) based on the difference of the arm circumference of 2 cm. Data including lymphedema, anthropometry, BIA measurements, food frequency questionnaire, type of surgery, total number of dissected lymph nodes, and post-operative treatment were collected.

Results: Of the breast cancer survivors, 10.4% had BCRL by the definition. The BCRL group contained 22 patients, while the non-BCRL group contained 206 patients. Compared to the non-BCRL group, the BCRL group had a higher body mass index, a larger percentage of ideal body weight, more dissected lymph nodes, and higher single frequency BIA (SFBIA) ratio (P = 0.027, P = 0.031, P < 0.001, and P < 0.001, respectively). The SFBIA ratio provided 63.64% sensitivity and 95.15% specificity in estimating the risk of BCRL.

Conclusion: Our data provides evidence to support that the use of SFBIA ratio can serve as an alternative method to monitor and/or diagnose BCRL.

Trial registration: This trial was retrospectively registered at Clinicaltrials.gov identifier (NCT03391206) on the 5 January 2018.

Keywords: Breast cancer related lymphedema, Sentinel lymph node biopsy, Axillary lymph node dissection, Bioelectrical impedance, BMI

* Correspondence: hyungseokpark.md@gmail.com; imgenius@yuhs.ac; imgenius2@gmail.com
†Co-First author: Sung Mook Lim; Yujin Han
1Department of Surgery, Yonsei University College of Medicine, 50-1, Yonsei-ro, Seodaemun-gu, Seoul 03722, Republic of Korea
Full list of author information is available at the end of the article

© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background

Lymphedema can be clinically diagnosed based on the swelling of limbs. However, definitive diagnosis of lymphedema is difficult, because most would suggest that lymphatic dysfunction imaged by lymphoscintigraphy or indocyanine green lymphography is required. The clinical diagnosis of lymphedema includes the observation that the bilateral difference in limb circumference is 2 cm or more [1], the difference of pre and post operation in volume of the limb is more than 200 ml [2], or the bilateral difference in volume of the limb change is 10% [3]. Because of differences in diagnostic criteria in these measurement methods, the definitive diagnosis is difficult. In addition, ultrasound, computed tomography, and magnetic resonance imaging are used to diagnose lymphedema. The ultrasound can measure volumetric and structural changes in the dermis, subcutaneous layer, and muscle, but information on the truncal anatomy of the lymphatic system can not be confirmed [4]. The computed tomography can detect thickening of the skin and subcutaneous compartment, and thickened perimuscular aponeurosis [4]. The magnetic resonance imaging can distinguish lymphedema, lipedema, and phlebedema, and can confirm the circumferential measurement edema, thickened dermis, and increased subcutaneous compartment [4, 5].

The arm circumference measurement is a commonly utilized clinical diagnosis method [6]. The circumference of both arms at 15 cm below the acromion process and the olecranon process is measured, and the circumference values of the affected arm and unaffected arm are compared [6, 7]. However, with this method there is no standardized reference point and low sensitivity. The lack of evidence-based diagnostic criteria to define lymphedema has presented tremendous challenges in terms of diagnosis. Therefore, defining criteria for the early detection and treatment of lymphedema is important [8].

Recently, several researchers have used bioelectrical impedance analysis (BIA) to diagnose lymphedema [9–14]. This method is highly sensitive, can be used as a basis to establish standardized criteria, and can be used to measure extracellular space [9, 15, 16]. Bioelectrical impedance predicts body composition using differences in electric conductivity upon sending a minute current through the human body [17, 18]. In several studies, the single frequency bioelectrical impedance analysis (SFBIA) of the two arms obtained using bioelectrical impedance measurements was expressed as the ratio of the values of the operated and non-operated arms [10, 19]. However, this method has not been validated as a diagnostic tool. It is therefore necessary to study this method further to establish it as an efficient diagnostic means.

The purpose of this study is to determine diagnostic accuracy of bioelectrical impedance as a diagnostic method based on the presence of lymphedema compared with circumference measurements. In addition, the aim is to identify risk factors to help prevent lymphedema for breast cancer survivors.

Methods

Study design and subjects

This prospective study was conducted at Severance Hospital in Korea from May 2016 to January 2017 and involved female unilateral breast cancer survivors aged 20 or older who underwent surgery at least six months prior to selection. Patients with bilateral breast cancer, male breast cancer, recurrent breast cancer, previous ipsilateral axillary surgery, and previous radiotherapy were excluded. This study was approved by the Institutional Review Board of Severance Hospital (IRB Number: 4–2016-0149). All patients participated voluntarily in the study and provided written informed consent. All subjects underwent BIA, body measurements and semi-quantitative food frequency questionnaire for the Korean Genome Epidemiologic Study [20].

A total of 250 patients were recruited. A total of 228 patients were finally enrolled in the study. (Clinicaltrials.gov identifier: NCT03391206). Of the patients who were excluded, 10 had bilateral breast cancer, 10 had poor medical records, and two did not have bioelectrical impedance measured (Fig. 1). The presence or absence of lymphedema was assessed in 228 patients based on circumference measurements [6]. Arm circumference measurements were examined using a method that was described in the previous study definition [21]. The circumference of both arms at 15 cm below the acromion and the olecranon process was measured, and the measured values of the affected and unaffected arm were compared. Patients were classified as BCRL group (n = 22) with a difference more than or equal to 2 cm and non-BCRL group (n = 206) with a difference less than 2 cm.

Anthropometric parameter and body composition measurements

Body height was measured using an automatic extension meter. Body composition analysis was performed with an Inbody 720 composition analyzer (Biospace, Seoul, South Korea). Before assessment, participants were instructed to avoid excessive fluid intake, alcohol ingestion and heavy physical activity. Subjects were asked to remove anything metal and to stand barefoot on the metal footpads while loosely holding the handgrips. The results were automatically input into the system. Body weight, fat mass, body mass index (BMI), the waist-hip ratio (WHR), percent of ideal body weight (PIBW), extracellular water (ECW), total body water (TBW), and SFBIA were measured using BIA. SFBIA values were noted for both upper extremities at 1 kHz and 5 kHz. The SFBI A ratio was calculated as the
ratio of the values of the affected to unaffected arms [14]. The SFBI A ratio was used to assess lymphedema.

BMI, PIBW, and SFBI A ratio were calculated as follows;

**BMI**

$$\text{BMI} = \frac{\text{body weight in kilograms}}{\text{height in meters}^2}.$$  

**PIBW**

$$\text{PIBW} = \frac{\text{actual weight}}{\text{ideal body weight}^\ast \times 100}.$$  

$\ast\text{ideal body weight} = (\text{height in meters})^2 \times \text{ideal BMI}^\ast.$  

$\ast\text{ideal BMI} = \text{female; 21 kg/m}^2, \text{male; 20 kg/m}^2.$

**SFBI A ratio**

$$\text{SFBI A ratio} = \frac{\text{unaffected SFBI A}}{\text{affected SFBI A}}.$$  

**Medical record collection**

Clinicopathological information was obtained from the medical records of the participating women. Clinicopathological variables included surgery type (sentinel lymph node biopsy (SLNB) or axillary lymph node dissection (ALND)), number of dissected lymph nodes, and postoperative therapy such as chemotherapy, radiotherapy, hormone therapy, and target therapy.

**Statistical analysis**

The variables used in this study were anthropometric values, the SFBI A value, the intake of nutrients, activity level, healthy functional foods, surgical methods, the number of removed lymph nodes, and treatment methods. The results are described as mean and standard deviation. The relationship between variables in the non-BCRL and BCRL groups was analyzed. The chi-squared test or Fishers exact test and independent sample t-test or Mann-Whitney U test were used for the analyses. The reported $p$-values are two-sided and were considered statistically significant at 0.05 or less. All data analyses were performed using IBM SPSS Statistics version 23.0 for Windows (IBM Corp., Armonk, NY, USA).

**Results**

**Subject characteristics**

Table 1 details the general characteristics of the study patients, who were classified according to axillary surgery type (SLNB or ALND) and the presence or absence of lymphedema (Non-BCRL or BCRL). No significant differences between the non-BCRL group and BCRL group were found in terms of age or physical activity level. The
lymphedema of the operated site was significantly higher in the right side than in the left side. The number of lymph nodes removed was significantly higher in the BCRL than in the non-BCRL, but this difference was not observed when the subjects were divided according to surgery type (SLNB or ALND). The mean value of the acromion circumference difference was 2.69 ± 1.70 cm in the BCRL group. The arm circumference difference was larger in the lymphedema group with ALND than in the group with SLNB.

**Anthropometry and bioelectrical impedance data**

The anthropometric data including body weight, fat mass, BMI, body fat percentage (BFP), WHR, PIBW, ECW/TBW, and SFBIA ratio were compared between the non-BCRL and BCRL groups for each surgery type (Table 2). BMI was significantly higher in the BCRL group ($P = 0.027$). Obesity-related factors including body weight, fat mass, BFP, PIBW, and BMI were significantly higher in the BCRL group than in the non-BCRL group for SLNB patients, while there were no significant differences among the ALND patients.

**Diagnosis of lymphedema using SFBIA ratio**

Table 3 summarizes SFBIA ratios calculated from the ratio of the values of the operated and non-operated arms. The 1 kHz SFBIA ratio of the BCRL and non-BCRL groups was $1.145 ± 0.234$ and $0.996 ± 0.039$ ($p < 0.001$), respectively. The 5 kHz SFBIA ratio was significantly higher in the BCRL group than in the non-BCRL group ($p < 0.001$). Regarding the SFBIA

---

**Table 1** General characteristics of the study population

|                      | SLNB (n = 148) | ALND (n = 80) | Total (n = 228) |
|----------------------|----------------|--------------|----------------|
|                      | Non-BCRL (n = 142) | BCRL (n = 6) | Non-BCRL (n = 64) | BCRL (n = 16) | Non-BCRL (n = 206) | BCRL (n = 22) | P value<sup>a</sup> | P value<sup>b</sup> | P value<sup>b</sup> |
| Age (years)          | 53.2 ± 10.0 | 56.7 ± 15.0 | 0.556 | 59.1 ± 10.4 | 58.7 ± 6.7 | 0.124 | 52.8 ± 9.7 | 56.3 ± 12.0 | 0.121 |
| Operated site        |               |              |        |               |              |        |               |              |        |
| Left                 | 68 (47.9) | 1 (16.7) | 0.133 | 33 (51.6) | 4 (25.0) | 0.057 | 101 (49.0) | 5 (22.7) | 0.019 |
| Right                | 74 (52.1) | 5 (83.3) | 31 (48.4) | 12 (75.0) | 105 (51.0) | 17 (77.3) |        |        |        |
| No. of dissected lymph nodes | 4.2 ± 2.3 | 5.0 ± 2.5 | 0.507 | 15.7 ± 7.5 | 19.7 ± 7.4 | 0.057 | 7.7 ± 7.0 | 15.7 ± 9.2 | 0.001 |
| Therapy<sup>c</sup>  |               |              |        |               |              |        |               |              |        |
| Chemotherapy         | 53        | 4           | 34     | 9             | 87     | 13    |        |        |        |
| Radiotherapy         | 88        | 4           | 47     | 15            | 135    | 19    |        |        |        |
| Hormonal therapy     | 113       | 4           | 44     | 12            | 157    | 16    |        |        |        |
| Target therapy       | 8         | 1           | 11     | 3             | 19     | 4     |        |        |        |
| Missing data         | 1         | 0           | 2      | 0             | 3      | 0     |        |        |        |
| Circumference difference<sup>d</sup> |               |              |        |               |              |        |               |              |        |
| Acromion             | 0.57 ± 0.52 | 2.37 ± 0.59 | 0.000 | 0.71 ± 0.64 | 2.81 ± 1.97 | 0.001 | 0.58 ± 0.49 | 2.69 ± 1.70 | 0.000 |
| Olecranon             | 0.58 ± 0.50 | 1.52 ± 1.02 | 0.010 | 0.54 ± 0.41 | 2.09 ± 2.10 | 0.010 | 0.55 ± 0.46 | 1.93 ± 1.867 | 0.002 |
| Physical activity     |               |              |        |               |              |        |               |              |        |
| Inactive<sup>e</sup> | 1 (0.7)   | 0 (0.0) | 0.631 | 0 (0.0) | 0 (0.0) | 0.204 | 1 (0.5) | 0 (0.0) | 0.210 |
| Sedentary<sup>f</sup> | 23 (16.2) | 1 (16.7) | 11 (17.2) | 5 (31.3) | 34 (16.5) | 6 (27.3) |        |        |        |
| Active<sup>g</sup>   | 88 (62.0) | 5 (83.3) | 38 (59.4) | 10 (62.5) | 126 (61.2) | 15 (68.2) |        |        |        |
| Very active<sup>h</sup> | 30 (21.1) | 0 (0.0) | 15 (23.4) | 1 (6.3) | 45 (21.8) | 1 (4.5) |        |        |        |
| Health supplement food<sup>i</sup> |               |              |        |               |              |        |               |              |        |
| Vitamin & mineral agent | 76        | 4           | 30     | 6             | 106    | 10    |        |        |        |
| Other dietary supplement | 2        | 39          | 21     | 7             | 60     | 9     |        |        |        |

SLNB sentinel lymph node biopsy, ALND axillary lymph node dissection, non-BCRL non-breast cancer-related lymphedema, BCRL Breast cancer-related lymphedema

Values are mean ± standard deviation or N (percentage)

<sup>a</sup>Differences between BCRL and Non-BCRL were tested by the Mann-Whitney U test and the Pearson’s chi-squared test

<sup>b</sup>Differences between BCRL and Non-BCRL were tested by the Student’s t-test and the Pearson’s chi-squared test

<sup>c</sup>Occasionally, one or more treatments were given to one person

<sup>d</sup>Circumference difference were calculated by the equation affected length minus the unaffected length

<sup>e</sup>Inactive: Limited physical activity (eg. inpatient)

<sup>f</sup>Sedentary: Most of the time is spent sitting in a static activity

<sup>g</sup>Active: Most of the time spent sitting, but lifestyle also includes standing work, commuting, buying things, housework, light exercise

<sup>h</sup>Very active: Strenuous work or highly active leisure

<sup>i</sup>Vitamin & mineral agent

<sup>j</sup>Other dietary supplement

Lim et al. BMC Cancer (2019) 19:669
Table 2 Analysis of BCRL and non-BCRL values through bioelectrical impedance analysis

|                      | SLNB (n = 148) |          | ALND (n = 80) |          | Total (n = 228) |
|----------------------|----------------|----------|---------------|----------|----------------|
|                      | Non-BCRL (n = 142) | BCRL (n = 6) | P valuea | Non-BCRL (n = 64) | BCRL (n = 16) | P valueb | Non-BCRL (n = 206) | BCRL (n = 22) | P valuec |
| BW (kg)              | 59.4 ± 10.6     | 72.4 ± 12.0 | 0.009 | 59.1 ± 10.4     | 58.7 ± 6.7     | 0.878 | 59.3 ± 10.5     | 62.4 ± 10.2     | 0.183 |
| FFM (kg)             | 39.3 ± 4.5      | 43.8 ± 4.4     | 0.052 | 39.3 ± 4.7     | 38.4 ± 4.2     | 0.494 | 40.3 ± 14.6     | 39.9 ± 4.8     | 0.904 |
| FM (kg)              | 20.1 ± 7.7      | 28.6 ± 8.0     | 0.016 | 19.8 ± 7.5     | 20.3 ± 4.8     | 0.816 | 20.0 ± 7.6     | 22.5 ± 6.8     | 0.131 |
| BMI (kg/m²)c         | 23.8 ± 4.2      | 28.4 ± 4.5     | 0.011 | 23.6 ± 4.0      | 24.7 ± 2.7     | 0.275 | 23.7 ± 4.1     | 25.7 ± 3.6     | 0.027 |
| BFP (%)              | 32.8 ± 7.2      | 38.8 ± 5.1     | 0.034 | 32.8 ± 6.5     | 34.2 ± 5.6     | 0.421 | 32.8 ± 7.0     | 35.5 ± 5.8     | 0.084 |
| WHR                  | 0.87 ± 0.06     | 0.89 ± 0.05     | 0.180 | 0.86 ± 0.05     | 0.89 ± 0.05     | 0.180 | 0.87 ± 0.06     | 0.89 ± 0.05     | 0.088 |
| PIBWd                | 112.6 ± 20.0    | 134.7 ± 21.8    | 0.012 | 111.6 ± 19.0   | 116.9 ± 13.1    | 0.296 | 112.3 ± 19.6   | 121.7 ± 17.3    | 0.031 |
| ECW/TBW              | 0.39 ± 0.01     | 0.39 ± 0.01     | 0.312 | 0.39 ± 0.01     | 0.39 ± 0.01     | 0.168 | 0.39 ± 0.01     | 0.39 ± 0.01     | 0.068 |

Values are mean ± standard deviation

aP values of differences between means were calculated using the Mann-Whitney U test
bP values of differences between means were calculated using an independent sample t-test
cBody mass index (BMI) was calculated body weight in kilograms/(height in meters)²
dPercent of ideal body weight (PIBW) was determined by the equation actual weight (kg)/ideal body weight (kg) × 100

Discussions

Early prevention and detection of postoperative lymphedema complications in breast cancer patients is important for quality of life. Our data provided evidence to support the use of the SFBIA ratio by BIA in lymphedema in breast cancer survivors. In addition, right axillary surgery was suggested to be a risk factor associated with lymphedema. Lymphedema was more common in patients with the right axillary procedure than those with the left. This may be due to the fact that right handed people are more common and have more axillary activity on the right side. Additionally, the number of dissected lymph nodes [22–25], obesity [23, 24, 26, 27], and surgery type [22, 24, 25] were risk factors for lymphedema. It was concordant with previous study [22–27].

In this study, BCRL was determined based on more than a 2 cm difference in the circumference, as measured 15 cm below the olecranon, or acromion process, of the arm not affected by the operation relative to the

Table 3 SFBIA ratio of breast cancer survivors according to lymphedema

|                      | SLNB (n = 148) |          | ALND (n = 80) |          | Total (n = 228) |
|----------------------|----------------|----------|---------------|----------|----------------|
|                      | Non-BCRL (n = 142) | BCRL (n = 6) | P valuea | Non-BCRL (n = 64) | BCRL (n = 16) | P valueb | Non-BCRL (n = 206) | BCRL (n = 22) | P valuec |
| 1 kHz                | 0.991 ± 0.039  | 1.013 ± 0.045   | 0.183 | 1.006 ± 0.036  | 1.194 ± 0.257   | < 0.001 | 0.996 ± 0.039  | 1.145 ± 0.234   | < 0.001 |
| 5 kHz                | 0.990 ± 0.036  | 1.016 ± 0.037   | 0.075 | 1.004 ± 0.037  | 1.177 ± 0.250   | < 0.001 | 0.994 ± 0.037  | 1.133 ± 0.225   | < 0.001 |

Values are mean ± standard deviation

aSingle-frequency bioelectrical impedance analysis (SFBIA) ratio of the affected to unaffected side were calculated
bP values of differences between means were calculated using the Mann-Whitney U test
cP values of differences between means were calculated using an independent sample t-test
circumference of the arm on the same side as the operation \[7, 28, 29\]. Limitations include potential errors in the measurements and the fact that diagnosis is not possible until clinical symptoms are seen. More precise techniques including ultrasound, computed tomography, magnetic resonance imaging, lymphoscintigraphy and other volumetric measurement can enhance the diagnosis of lymphedema. Further studies that evaluate the comparison these techniques and BIA are needed.

BIA is designed to measure edema as an extremely small electrical current passes through extracellular fluid \[9\]. This technique distinguishes extracellular fluid from total limb volume \[9, 30\]. In the presence of lymphedema, the SFBIA ratio \[10\] is related to the accumulation of extracellular fluid \[31\]. Our results show that the SFBIA ratio is larger at 5 kHz than at 1 kHz. BIA had good performance in terms of specificity (95.15%) and negative predictive value (96.08%). A diagnostic tool with a high specificity is more useful for ‘judging’ a disease when a person is positive and the negative predictive value can be used that the probability of not having disease given a negative diagnosis \[32\]. These values indicate that BIA can be used as a method of monitoring and diagnosing lymphedema. Previous studies have reported that early surveillance for risk of lymphedema using bioimpedance spectroscopy with early intervention with compression garments can reduce the incidence of more advanced lymphedema \[11, 12\]. Our cut-off value of the SFBIA ratio for diagnosing lymphedema should be validated in further studies. The usefulness of early detection through the SFBIA ratio is necessary to be evaluated as well.

Well-known risk factors for lymphedema include the surgery type \[22, 24, 25\] and the number of dissected lymph nodes \[22–25\]. Similarly, our study also demonstrated that the higher the number of lymph nodes removed in the ALND subjects, the higher the incidence of lymphedema. However, these were not observed for the SLNB because the number of lymph nodes removed is too small to affect the risk of lymphedema in these subjects. Overall, on average our SLNB subjects had less than 5 lymph nodes removed whereas the ALND had 16 to 20 lymph nodes removed. Thus, surgery type associated with high lymph node removal is likely to increase the risk of lymphedema as reported previously \[22–25\].

Obesity-related indicators in breast cancer patients increase the risk of developing lymphedema complications \[26, 33, 34\]. Our data investigated the relationship between the incidence of lymphedema and the variables related to anthropometric measurements and type of surgery. The BMI and PIBW of the subjects were significantly higher in the presence of lymphedema. In particular, body fat percentage, BMI, and PIBW were significantly different in patients who underwent SLNB. These findings suggest that the occurrence of lymphedema is associated with obesity and that patients who undergo SLNB procedures should pay attention to maintaining normal weight. There was no significant difference of obesity-related indicators between BCRL and non-BCRL in the patients with ALND. Our results were different from the studies conducted on Westerners. The association between BMI and lymphedema volume in patients with ALND was observed \[35, 36\]. The difference between ours and previous studies
The lymphedema of our subjects was confirmed by the difference in limb circumference of 2 cm of both sides. This confirmed the lymphedema of the arm, but not the lymphedema that appeared at other sites. Therefore, the diagnosis of more detailed lymphedema will establish an accurate standard of the SFBIA ratio. Nevertheless, our study confirmed the cut-off value of the SFBIA ratio for the determination of lymphedema through 228 subjects and confirmed the sensitivity and specificity. Our findings have shown the possibility of SFBIA ratio as a useful tool for the diagnosis and management of lymphedema in breast cancer survivors. In addition, we found that there was a significant correlation between lymphedema and obesity in patients who underwent SLNB, but not in patients who underwent ALND.

**Conclusion**
The SFBIA ratio obtained using BIA can be an alternative method for monitoring and/or diagnosing BCRL. The BIA had a sensitivity of 63.64% and a specificity of 95.15% in predicting BCRL. In addition, number of dissected lymph nodes, operation site, surgery type, obesity, and the SFBIA ratio are significantly associated with the occurrence of lymphedema.

**Abbreviations**
ALND: Axillary lymph node dissection; BCRL: Breast cancer-related lymphedema; BFP: Body fat percentage; BIA: Bioelectrical impedance analysis; BMI: Body mass index; ECW: Extracellular water; PIBW: Percent of ideal body weight; ROC: Receiver operating characteristic; SFBIA: Single frequency bioelectrical impedance analysis; SLNB: Sentinel lymph node biopsy; TBW: Total body water; WHR: Waist-hip ratio

**Acknowledgements**
The authors thank the patients who participated in this study.

**Author contributions**
SML, YJH, and HSP wrote the manuscript. HSP conceived and designed the study and edited the manuscript. SML and YJH analyzed and interpreted patient data regarding the bioelectrical impedance measurements, food intake surveys, and medical records. SIK and HSP conceived the study and helped to draft the manuscript. All authors read and approved the final manuscript.

**Funding**
This research was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (2016R1D1A1B03934564) and a faculty research grant of Yonsei University College of Medicine (6-2017-0732). The funding body had no role in the design of the study, data collection, analysis, and interpretation, or in writing the manuscript.

**Availability of data and materials**
The datasets generated and/or analyzed during the current study are not publicly available due to domestic regulation that prohibits opening clinical data of patients but they are available from the corresponding author upon reasonable request.

**Ethics approval and consent to participate**
This study was approved by the Institutional Review Board of Severance Hospital (IRB number 4-2016-0149), and this trial is registered with Clinicaltrials.gov identifier, NCT03391206. All participants participated voluntarily and completed a written informed consent.

**Consent for publication**
Not Applicable.

**Competing interests**
The authors declare that they have no competing interests.

**Author details**
1Department of Surgery, Yonsei University College of Medicine, 50-1, Yonsei-ro, Seodaemun-gu, Seoul 03722, Republic of Korea. 2Department of Food and Nutrition, College of Human Ecology, Yonsei University, 50, Yonsei-ro, Seodaemun-gu, Seoul 03722, Republic of Korea.

**Received:** 30 September 2018 **Accepted:** 17 June 2019 **Published online:** 08 July 2019

**References**
1. Powell SN, Taghian AG, Kachnic LA, Coen JJ, Assaad SI. Risk of lymphedema after regional nodal irradiation with breast conservation therapy. Int J Radiat Oncol Biol Phys. 2003;55(5):1209–15.
2. Armer JM, Stewart IB. A comparison of four diagnostic criteria for lymphedema in a post-breast cancer population. Lymphat Res Biol. 2005;3(4):208–17.
3. Hayes S, Cornish E, Newman B. Comparison of methods to diagnose lymphedema among breast cancer survivors: 6-month follow-up. Breast Cancer Res Tr. 2005;89(3):221–6.
4. Tiwari A, Cheng K-S, Button M, Myint F, Hamilton G. Differential diagnosis, investigation, and current treatment of lower limb lymphedema. Arch Surg. 2003;138(2):152–61.
5. Sen Y, Qian Y, Koelmeyer L, Borotkanics R, Ricketts R, Mackie H, Lant TC, Shon KH, Suami H, Boyages J. Breast cancer-related lymphedema: differentiating fat from fluid using magnetic resonance imaging segmentation. Lymphat Res Biol. 2018;16(1):20–7.
6. Kissin M, Della Rovere GQ, Easton D, Westbury G. Risk of lymphoedema following the treatment of breast cancer. Br J Surg. 1986;73(7):580–4.
7. Sakorafas GH, Peros G, Cataliotti L, Vlaost G. Lymphedema following axillary lymph node dissection for breast cancer. Surg Oncol. 2006;15(3):153–65.
8. Fu MR. Breast cancer-related lymphedema: symptoms, diagnosis, risk reduction, and management. World J Clin Oncol. 2014;5(3):241–7.
9. York SL, Ward LC, Czernieck S, Lee MJ, Refshaugue KM, Killbreath SL. Single frequency versus bioimpedance spectroscopy for the assessment of lymphedema. Breast Cancer Res Treat. 2009;117(1):177–82.
10. Kim L, Jeon JY, Sung PY, Jeong SY, Do JH, Kim HJ. Prediction of treatment outcome with bioimpedance measurements in breast cancer related lymphedema patients. Ann Rehabil Med. 2011;35(5):687–93.
11. Koelmeyer LA, Borotkanics RJ, Alcorso J, Prah P, Winch CJ, Nakhl K, Dean CM, Boyages J. Early surveillance is associated with less incidence and severity of breast cancer-related lymphedema compared with a traditional referral model of care. Cancer. 2019;125(6):854–62.
12. Ridher SH, Dietrich MS, Spotanski K, Doensam JK, Cowher MS, Taback B, McLaughlin S, Ajkay N, Boyages J, Koelmeyer L. A prospective study of L-dex values in breast cancer patients pretreatment and through 12 months postoperatively. Lymphat Res Biol. 2018;16(5):435–41.
13. Jung M, Jeon JY, Yun GJ, Yang S, Kwon S, Seo YJ. Reference values of bioelectrical impedance analysis for detecting breast cancer-related lymphedema. Medicine. 2018;97(44).
14. Kim L, Jeon JY, Sung PY, Jeong SY, Do JH, Kim HJ. Prediction of treatment outcome with bioimpedance measurements in breast cancer related lymphedema patients. Ann Rehabil Med. 2011;35(5):687.
15. Shah C, Vicini FA. Breast cancer-related arm lymphedema: incidence rates, diagnostic techniques, optimal management and risk reduction strategies. Int J Radiat Oncol Biol Phys. 2011;81(4):907–14.
16. Shah C, Vicini FA, Arthur D. Bioimpedance spectroscopy for breast cancer related lymphedema assessment: clinical practice guidelines. Breast J. 2016.
17. Kyle UG, Bosaeus I, De Lorenzo AD, Deurenberg P, Elia M, Gomez JM, Heitmann BL, Kent-Smith L, Melchior JC, Pritsch M, et al. Bioelectrical impedance analysis—part I: review of principles and methods. Clin Nutr. 2004;23(3):1226–43.
18. Lee B-B, Rockson SG, Bergan J. Lymphedema: a concise compendium of theory and practice. Springer; 2018.
19. Tuorkey M. Bioelectrical impedance as a diagnostic factor in the clinical practice and prognostic factor for survival in cancer patients; prediction, accuracy and reliability. J Biosens Bioelectron. 2012;2(12):1.
20. Ahn Y, Kwon E, Shim JE, Park MK, Joo Y, Kim K, Park C, Kim DH. Validation and reproducibility of food frequency questionnaire for Korean genome epidemiologic study. Eur J Clin Nutr. 2007;61(12):1435–41.
21. Krag DN, Anderson SJ, Julian TB, Brown AM, Harlow SP, Costantino JP, Ashikaga T, Weaver DL, Mammoukas EP, Alvarez LM. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomized phase 3 trial. The lancet oncology. 2010.11(10):927–33.
22. Morell PM, Halyard MY, Schild SE, Ali MS, Gunderson LL, Pockaj BA. Breast cancer-related lymphedema. Mayo Clin Proc. 2005;80(11):1480–4.
23. Paskett ED, Naughton MJ, McCoy TP, Case LD, Abbott JM. The epidemiology of arm and hand swelling in premenopausal breast cancer survivors. Cancer Epidemiol Biomark Prev. 2007;16(4):775–82.
24. Ugur S, Ano C, Yapar M, Mesco A, Ano GA, Doyan K, Ozmen V. Risk factors of breast cancer-related lymphedema. Lymphat Res Biol. 2013;11(2):72–5.
25. DiSipio T, Rye S, Newman B, Hayes S. Incidence of unilateral arm lymphoedema after breast cancer: a systematic review and meta-analysis. Lancet Oncol. 2013;14(6):500–15.
26. Helyer LK, Varnic M, Le LW, Leong W, McCready D. Obesity is a risk factor for developing postoperative lymphedema in breast cancer patients. Breast J. 2010;16(1):48–54.
27. Kocak Z, Overgaard J. Risk factors of arm lymphedema in breast cancer patients. Acta Oncol. 2000;39(3):389–92.
28. Deutsch M, Land S, Begovic M, Sharif S. The incidence of arm edema in women with breast cancer randomized on the national surgical adjuvant breast and bowel project study B-04 to radical mastectomy versus total mastectomy and radiotherapy versus total mastectomy alone. Int J Radiat Oncol. 2008;70(4):1020–4.
29. Lee JH, Suh YJ, Shim BY, Kim SH. The incidence and predictor of lymph node metastasis for patients with T1mi breast cancer who underwent axillary dissection and breast irradiation: an institutional analysis. Jpn J Clin Oncol. 2011;41(10):1162–7.
30. Ward LC. Bioelectrical impedance analysis: proven utility in lymphedema risk assessment and therapeutic monitoring. Lymphat Res Biol. 2006;4(1):51–6.
31. Van Loan MD, Mayclin PL. Use of multi-frequency bioelectrical impedance analysis for the estimation of extracellular fluid. Eur J Clin Nutr. 1992;46(2):117–24.
32. Akobeng AK. Understanding diagnostic tests 1: sensitivity, specificity and predictive values. Acta Paediatr. 2007;96(3):338–41.
33. Werner RS, McCormick B, Petrek J, Cox L, Cintresone C, Gray JR, Yahalom J. Arm edema in conservatively managed breast cancer: obesity is a major predictive factor. Radiology. 1991;180(1):177–84.
34. Riddle SH, Dietrich MS, Stewart BR, Armer JM. Body mass index and breast cancer treatment-related lymphedema. Support Care Cancer. 2011;19(6):853–7.
35. Vignes S, Arnauld M, Dupuy A. Factors associated with increased breast cancer-related lymphedema volume. Acta Oncol. 2007;46(8):1138–42.
36. Bevilaqua ILB, Kattan MW, Changhong Y, Koiffman S, Mattos IE, Koiffman RJ, Bergmann A. Nomograms for predicting the risk of arm lymphedema after axillary dissection in breast cancer. Ann Surg Oncol. 2012;19(8):2580–9.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:
• fast, convenient online submission
• thorough peer review by experienced researchers in your field
• rapid publication on acceptance
• support for research data, including large and complex data types
• gold Open Access which fosters wider collaboration and increased citations
• maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.
Learn more biomedcentral.com/submissions